Cost of Revenue Trends: AstraZeneca PLC vs Amphastar Pharmaceuticals, Inc.

Cost of Revenue Trends: AstraZeneca PLC vs Amphastar Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Over the past decade, AstraZeneca PLC and Amphastar Pharmaceuticals, Inc. have shown distinct trends in their cost of revenue. From 2014 to 2023, AstraZeneca's cost of revenue fluctuated significantly, peaking in 2021 with a staggering 12.4 billion, before dropping to 8 billion in 2023. This represents a 35% decrease, highlighting potential strategic shifts or market challenges. In contrast, Amphastar Pharmaceuticals experienced a steady increase, with costs rising from 159 million in 2014 to 293 million in 2023, marking an 84% growth. This consistent upward trend may indicate expansion or increased production capabilities. These insights provide a window into the operational strategies of these pharmaceutical giants, reflecting broader industry trends and economic conditions.